The acting head of the Food and Drug Administration is calling for a government investigation into highly unusual contacts between her agency’s drug reviewers and the maker of a controversial new Alzheimer’s drug
Related posts
-
America reaches Election Day and a stark choice between Trump and Harris
A presidential campaign marked by upheaval and rancor approached its finale on Election Day as Americans... -
Bears coaches feel heat, but don’t forget about bad drafts of past
The Bears season is losing steam quickly, but Sunday’s loss in Arizona was another reminder that... -
Who had the area’s top performances in the first round of the IHSA football playoffs?
With the first round of the IHSA football playoffs in the books, it's once again time...